Citing legal concerns, the University of Maryland’s School of Pharmacy has canceled plans to offer training for those who work in the medical marijuana industry,
After consulting with the Maryland attorney general’s office, the university asked pharmacy school officials to cancel the classes, a university spokesman said.
While marijuana has been legalized for medical purposes in Maryland, 28 other states and the District of Columbia, the administration of President Donald J. Trump has not indicated how it will handle enforcement of the federal marijuana law, which still classifies the drug alongside heroin and LSD.
“If there’s any question of the law, they are often consulted,” said Alex Likowski, a spokesman for the University of Maryland, Baltimore. “Regarding medical cannabis, even though Maryland and many other states have approved it, it’s still illegal under U.S. law.”
Katherine Bainbridge, chief counsel of the education affairs division in the attorney general’s office, confirmed that she gave advice to the university about the medical marijuana law specific to the courses the pharmacy school planned to offer, but she declined to disclose what the advice was.
While the school said it has suspended the program indefinitely, prospective students seeking to enroll through a university-associated website still see a note that enrollments were “suspended temporarily while the business agreements are being finalized by the university.” [Read more at The Baltimore Sun]
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
POSaBIT, the cannabis point-of-sale (POS) and payments software company, this morning announced its planned acquisition of MJ Platform (MJ Freeway), Leaf Data Systems, and Ample Organics from embattled software company…
New York marijuana regulators on Wednesday approved dozens of conditional adult-use dispensary licenses in a session during which members also discussed adopting bylaws for how the board runs meetings and makes decisions.…
By Griffin Thorne, Attorney at Harris Bricken Since the passage of the 2018 Farm Bill, the hemp CBD industry has been eagerly awaiting FDA CBD regulations. In that time, FDA…
The US Food and Drug Administration has finalized a 2020 draft guidance outlining how sponsors and investigators can conduct clinical trials for certain drugs containing cannabis or cannabis-derived compounds without…